These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 11276034)

  • 1. Modification of pharmacokinetic sampling schedules in clinical phase I trials: a use of Kullback-Leibler information.
    Yafune A; Ishiguro M
    Stat Med; 2001 Apr; 20(7):1033-49. PubMed ID: 11276034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A simulation-based confidence band for drug concentrations in blood: an application to a clinical phase I trial.
    Yafune A; Ishiguro M
    Stat Med; 2003 Oct; 22(19):3045-53. PubMed ID: 12973786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling attainment of steady state of drug concentration in plasma by means of a Bayesian approach using MCMC methods.
    Jordan P; Brunschwig H; Luedin E
    Pharm Stat; 2008; 7(1):36-41. PubMed ID: 17335108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimum blood sampling time windows for parameter estimation in population pharmacokinetic experiments.
    Graham G; Aarons L
    Stat Med; 2006 Dec; 25(23):4004-19. PubMed ID: 16463254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimization method for balancing continuous prognostic variables between treatment and control groups using Kullback-Leibler divergence.
    Endo A; Nagatani F; Hamada C; Yoshimura I
    Contemp Clin Trials; 2006 Oct; 27(5):420-31. PubMed ID: 16807130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bootstrap approach for constructing confidence intervals for population pharmacokinetic parameters. II: A bootstrap modification of standard two-stage (STS) method for phase I trial.
    Yafune A; Ishiguro M
    Stat Med; 1999 Mar; 18(5):601-12. PubMed ID: 10209814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential designs for ordinal phase I clinical trials.
    Liu G; Rosenberger WF; Haines LM
    Biom J; 2009 Apr; 51(2):335-47. PubMed ID: 19358220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An effective approach for obtaining optimal sampling windows for population pharmacokinetic experiments.
    Ogungbenro K; Aarons L
    J Biopharm Stat; 2009; 19(1):174-89. PubMed ID: 19127474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic-pharmacodynamic and metabolite modeling with TopFit.
    Tanswell P; Heinzel G; Weisenberger H; Roth W
    Int J Clin Pharmacol Ther; 1995 Oct; 33(10):550-4. PubMed ID: 8574505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
    Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
    Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bootstrap approach for constructing confidence intervals for population pharmacokinetic parameters. I: A use of bootstrap standard error.
    Yafune A; Ishiguro M
    Stat Med; 1999 Mar; 18(5):581-99. PubMed ID: 10209813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An adaptive dose-finding design incorporating both toxicity and efficacy.
    Zhang W; Sargent DJ; Mandrekar S
    Stat Med; 2006 Jul; 25(14):2365-83. PubMed ID: 16220478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Issues in the design of clinical trials for safety in HIV-infected children.
    Lindsey JC; Kline MW
    Pediatr AIDS HIV Infect; 1996 Apr; 7(2):69-82. PubMed ID: 11361484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Confidence intervals for ratios of AUCs in the case of serial sampling: a comparison of seven methods.
    Jaki T; Wolfsegger MJ; Ploner M
    Pharm Stat; 2009; 8(1):12-24. PubMed ID: 18407562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-finding in phase I clinical trials based on toxicity probability intervals.
    Ji Y; Li Y; Nebiyou Bekele B
    Clin Trials; 2007; 4(3):235-44. PubMed ID: 17715248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine.
    Variol P; Nguyen L; Tranchand B; Puozzo C
    Eur J Clin Pharmacol; 2002 Oct; 58(7):467-76. PubMed ID: 12389069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic parameters estimation using adaptive Bayesian P-splines models.
    Jullion A; Lambert P; Beck B; Vandenhende F
    Pharm Stat; 2009; 8(2):98-112. PubMed ID: 18481279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H; Mayer PR; Wajdula J; Fatenejad S
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors.
    Mould DR; Holford NH; Schellens JH; Beijnen JH; Hutson PR; Rosing H; ten Bokkel Huinink WW; Rowinsky EK; Schiller JH; Russo M; Ross G
    Clin Pharmacol Ther; 2002 May; 71(5):334-48. PubMed ID: 12011819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.
    Brunekreef B; Beelen R; Hoek G; Schouten L; Bausch-Goldbohm S; Fischer P; Armstrong B; Hughes E; Jerrett M; van den Brandt P
    Res Rep Health Eff Inst; 2009 Mar; (139):5-71; discussion 73-89. PubMed ID: 19554969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.